View Older Stories View More Recent Stories

Oct 24, 2022 04:05PM Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
Oct 24, 2022 04:05PM Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
Oct 3, 2022 08:00AM Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
Oct 3, 2022 08:00AM Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
Sep 22, 2022 04:05PM Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
Sep 22, 2022 04:05PM Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
Sep 6, 2022 04:03PM Eledon Pharmaceuticals (ELDN) Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
Sep 6, 2022 04:01PM Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
Sep 6, 2022 04:01PM Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
Aug 29, 2022 08:00AM Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aug 29, 2022 08:00AM Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aug 11, 2022 04:01PM Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
Aug 11, 2022 04:01PM Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
Aug 4, 2022 04:05PM Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
Aug 4, 2022 04:05PM Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
Aug 1, 2022 05:49AM Eledon Pharmaceuticals (ELDN) Granted FDA Clearance of IND Application to Evaluate Tegoprubart
Aug 1, 2022 05:00AM Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
Aug 1, 2022 05:00AM Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
Jul 18, 2022 08:00AM Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
Jul 18, 2022 08:00AM Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
Jun 10, 2022 04:05PM Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 10, 2022 04:05PM Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 9, 2022 08:03AM Eledon Pharmaceuticals (ELDN) Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
Jun 9, 2022 08:00AM Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
Jun 9, 2022 08:00AM Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
Jun 2, 2022 04:05PM Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
Jun 2, 2022 04:05PM Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2022 06:09AM Eledon Pharmaceuticals (ELDN) Reports Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
May 31, 2022 06:00AM Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
May 31, 2022 06:00AM Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
May 12, 2022 04:01PM Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
May 12, 2022 04:01PM Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
May 9, 2022 08:00AM Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
May 9, 2022 08:00AM Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
May 5, 2022 04:05PM Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
May 5, 2022 04:05PM Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
May 3, 2022 04:05PM Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
May 3, 2022 04:05PM Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
Apr 18, 2022 04:05PM Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
Apr 18, 2022 04:05PM Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
Apr 14, 2022 04:05PM Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
Apr 14, 2022 04:05PM Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
Mar 24, 2022 04:01PM Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
Mar 24, 2022 04:01PM Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
Mar 17, 2022 08:00AM Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Mar 17, 2022 08:00AM Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Feb 14, 2022 08:03AM Eledon Pharmaceuticals (ELDN) Provides 2022 Outlook
Feb 14, 2022 08:00AM Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
Feb 8, 2022 04:05PM Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
Dec 27, 2021 05:17PM Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences
View More Recent Stories View Older Stories